URILISER (Potassium citrate monohydrate, Citric acid monohydrate, Sorbitol base)

Uriliser SYP is a therapeutic solution designed to assist in the prevention of recurring kidney stones. This formulation includes a blend of potassium citrate and citric acid, which acts as a urinary alkalizer. By increasing the pH of urine, it effectively reduces acidity, thereby limiting the potential for the development of uric acid and cystine stones in the kidneys. In addition, Uriliser SYP is beneficial for individuals experiencing metabolic acidosis, a condition characterized by excessive acid production within the body. This product not only aids in stone prevention but also provides relief for individuals who suffer from urinary tract infections or experience discomfort and burning sensations while urinating. The formulation’s ability to soothe painful urination and support overall urinary health makes it a valuable option for those at risk of kidney stone formation. Regular use may significantly decrease the likelihood of stones reoccurring, thus promoting better kidney health and improving patient quality of life. By helping to maintain a balanced urinary pH, Uriliser SYP also plays a role in enhancing the body’s overall metabolic function, making it a crucial component in the management of conditions associated with urinary acidity. Use this medicine only under medical supervision. Follow the dose and schedule exactly as advised. Do not stop abruptly without guidance. Keep a record of any unusual symptoms and share them with your clinician. Combine therapy with appropriate lifestyle measures and routine monitoring as recommended.